



London, 5 July 2007  
Doc. Ref. EMEA/HMPC/179281/2007

**COMMITTEE ON HERBAL MEDICINAL PRODUCTS  
(HMPC)**

**DRAFT**

**COMMUNITY HERBAL MONOGRAPH ON *CALENDULA OFFICINALIS* L., FLOS**

<b>DISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)</b>	May 2007 July 2007
<b>ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION</b>	5 July 2007
<b>END OF CONSULTATION (DEADLINE FOR COMMENTS)</b>	15 October 2007
<b>REDISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)</b>	
<b>ADOPTION BY HMPC</b>	

Comments should be provided using this [template](#) to [hmpc.secretariat@emea.europa.eu](mailto:hmpc.secretariat@emea.europa.eu)  
Fax: +44 20 75 23 70 51

<b>KEYWORDS</b>	Herbal medicinal products; HMPC; Community herbal monographs; traditional use; <i>Calendula officinalis</i> L.; Calendulae flos; calendula flower
-----------------	---

## COMMUNITY HERBAL MONOGRAPH ON *CALENDULA OFFICINALIS* L., FLOS

### 1. NAME OF THE MEDICINAL PRODUCT

To be specified for the individual finished product.

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION<sup>1,2</sup>

<u>Well-established use</u>	<u>Traditional use</u>
	<p>With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended</p> <p>i) Herbal substance <i>Calendula officinalis</i> L., flos (calendula flower)</p> <p>ii) Herbal preparations</p> <p>A) Liquid extract (DER 1:1, ethanol 40-50% v/v) B) Tincture (DER 1:5, ethanol 70-90% v/v) C) Liquid extract (DER 1:10, fatty vegetable oil e.g. olive oil) D) Ointment (DER 1:5 – 1:25, hardened vegetable fat, petroleum jelly)<sup>3</sup> E) Comminuted herbal substance for infusion</p>

### 3. PHARMACEUTICAL FORM

<u>Well-established use</u>	<u>Traditional use</u>
	<p>Herbal substance or comminuted herbal substance for infusion or other herbal preparations in liquid or semi solid dosage forms for topical use.</p> <p>The pharmaceutical form should be described by the European Pharmacopoeia full standard term.</p>

<sup>1</sup> The material complies with the Ph. Eur. monograph (ref. 01/2005:1297).

<sup>2</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>3</sup> Calendula ointment is prepared by gentle digestion of the herbal substance in the melted ointment base for up to 16 hours and subsequent filtration and congealment during fall in temperature.

## 4. CLINICAL PARTICULARS

### 4.1. Therapeutic indications

<u>Well-established use</u>	<u>Traditional use</u>  a) Traditional herbal medicinal product for the symptomatic treatment of minor inflammations of the skin (such as sunburn) and as an aid in healing of minor wounds.  b) Traditional herbal medicinal product for the symptomatic treatment of minor inflammations in the mouth or the throat.  The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.
-----------------------------	--

### 4.2 Posology and method of administration

<u>Well-established use</u>	<u>Traditional use</u>  <b>Posology</b>  Herbal substance Infusion for topical application: 1-2 g / 150 ml of water. The still warm infusion is used as such to rinse or gargle for the treatment of inflammations in the mouth or the throat or to prepare compresses.  Herbal preparations A) Liquid extract (DER 1:1, ethanol 40-50% v/v) In semi-solid dosage forms: amount equivalent to 2-10% herbal substance B) Tincture In compresses diluted at least 1:3 with freshly boiled water; in semi-solid dosage forms: amount equivalent to 2-10% herbal substance C) Liquid extract (DER 1:10, fatty vegetable oil e.g. olive oil) In semi-solid dosage forms: amount equivalent to 2-8% herbal substance D) Ointment Equivalent to 4-20% herbal substance  <u>Indication a)</u> The use is not recommended in children under 6 years of age (see section 4.4 Special warnings and precautions for use).
-----------------------------	---

	<p><b>Indication b)</b> The use is not recommended in children under 12 years of age (see section 4.4 Special warnings and precautions for use).</p> <p><b>Duration of use</b></p> <p>Compresses: remove after 30-60 minutes</p> <p>If the symptoms persist after 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p> <p><b>Method of administration</b></p> <p>Topical application, 2 to 4 times daily.</p>
--	--

#### 4.3. Contraindications

<u>Well-established use</u>	<u>Traditional use</u>
	Hypersensitivity to members of the Asteraceae family (Compositae family).

#### 4.4. Special warnings and precautions for use

<u>Well-established use</u>	<u>Traditional use</u>
	<p><b>Indication a)</b> The use in children under 6 years of age is not recommended because there is no experience available.</p> <p><b>Indication b)</b> The use in children under 12 years of age is not recommended because there is no experience available.</p> <p>If signs of skin infection are observed, medical advice should be sought.</p>

#### 4.5. Interactions with other medicinal products and other forms of interaction

<u>Well-established use</u>	<u>Traditional use</u>
	None reported.

#### 4.6. Pregnancy and lactation

<u>Well-established use</u>	<u>Traditional use</u> Safety during pregnancy and lactation has not been established.  In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
-----------------------------	--

#### 4.7. Effects on ability to drive and use machines

<u>Well-established use</u>	<u>Traditional use</u> Not relevant.
-----------------------------	---

#### 4.8. Undesirable effects

<u>Well-established use</u>	<u>Traditional use</u> Skin sensitization. The frequency is not known.  If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.
-----------------------------	--

#### 4.9. Overdose

<u>Well-established use</u>	<u>Traditional use</u> No case of overdose has been reported.
-----------------------------	--

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

<u>Well-established use</u>	<u>Traditional use</u> Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
-----------------------------	--

#### 5.2 Pharmacokinetic properties

<u>Well-established use</u>	<u>Traditional use</u> Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
-----------------------------	--

### 5.3 Preclinical safety data

<u>Well-established use</u>	<u>Traditional use</u>  Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.  Available tests on genotoxicity (liquid extract with 60% ethanol) and on carcinogenicity (undefined extract) did not give any reason for concern.  Tests on reproductive toxicity have not been performed.
-----------------------------	--

### 6. PHARMACEUTICAL PARTICULARS

<u>Well-established use</u>	<u>Traditional use</u>  Not applicable.
-----------------------------	---

### 7. DATE OF COMPILATION/LAST REVISION

5 July 2007